

Form PTO 1442 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 7732-020-27 DIV	SERIAL NO. 09/665,077
<div style="position: relative; width: 100px; height: 100px; margin: 0 auto;"> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; line-height: 100px;"> APR 03 2001 PATENT & TRADEMARK OFFICE </div> </div>		APPLICANT MICHAEL CLIMO, ET AL.	
		FILING DATE SEPTEMBER 19, 2000	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		GROUP ART UNIT 1631	

RECEIVED

APR 04 2001

TECH CENTER 1600/25

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
MM	AA	5,760,026	6/2/98	BLACKBURN, ET AL.			
	AB	5,858,962	1/99	BLACKBURN, ET AL.			
	AC	3,278,378	10/66	SCHINDLER ET AL.			
	AD	3,398,056	8/68	ZYGMUNT ET AL.			
	AE	3,594,284	7/71	ZYGMUNT ET AL.			
	AF	4,931,390	6/90	RECSEI			
MM	AG	6,028,051	2/00	CLIMO et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AH				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

MM	AI	Chambers, Henry F., "Parenteral Antibiotics for the Treatment of Bacteremia and Other Serious Staphylococcal Infections", The Staphylococci in Human Disease, Chapter 26, pages 583-595 (1997).
	AJ	Polak, et al., "In Vitro Activity of Recombinant Lysostaphin-Antibiotic Combinations Toward Methicillin-Resistant <i>Staphylococcus aureus</i> ", Diagn Microbiol Infect Dis, 17:265-270 (1993).
	AK	Berger-Bächi, Brigitte, "Resistance Not Mediated By β -Lactamase (Methicillin Resistance)", The Staphylococci in Human Disease, Grassley, et al. (eds), Chapter 6 (part 2), pages 158-174 (1997).
	AL	Tschierske, et al., "Lif, the Lysostaphin Immunity Factor, Complements FemB in Staphylococcal Peptidoglycan Interpeptide Bridge Formation", FEMS Microbiology Letters, Volume 153, pages 261-264 (1997).
	AM	DeHart, et al., "The Lysostaphin Endopeptidase Resistance Gene (epr) Specifies Modification of Peptidoglycan Cross Bridges in <i>Staphylococcus simulans</i> and <i>Staphylococcus aureus</i> ", Applied and Environmental Microbiology, Volume 61, No. 4, pages 1475-1479, April 1995.
	AN	Strandén, et al., "Cell Wall Monoglycine Cross-Bridges and Methicillin Hypersusceptibility in a <i>femAB</i> Null Mutant of Methicillin-Resistant <i>Staphylococcus aureus</i> ", Journal of Bacteriology, Volume 179, No. 1, pages 9-16, January 1997.
MM	AO	Zygmunt, et al., "Lytic Action of Lysostaphin on Susceptible and Resistant Strains of <i>Staphylococcus Aureus</i> ", Canadian Journal of Microbiology, Volume 13, pages 845-853 (1967).

EXAMINER	DATE CONSIDERED 02/02
----------	-----------------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449

(Modified)

U.S. DEPARTMENT OF
COMMERCE
PATENT AND
TRADEMARK OFFICE

DOCKET NO.

7732-020-27 DIV

SERIAL NO.

09/665,077

RECEIVED

APR 04 2001

APPLICANT

MICHAEL CLIMO, ET AL.

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY
APPLICANT

(Use Several Sheets if Necessary)

FILING DATE

SEPTEMBER 19, 2000

GROUP ART UNIT

1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AP						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AQ					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)



my	AR	Ehlert, et al., "Specificities of FemA and FemB for Different Glycine Residues: FemB Cannot Substitute for FemA in Staphylococcal Peptidoglycan Pentaglycine Side Chain Formation", Journal of Bacteriology, Volume 179, No. 23, pages 7573-7576 (December 1997).
	AS	Dixon, et al., "Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. III. Lysostaphin-Methicillin Therapy of Established Staphylococcal Abscesses in Mice", Yale Journal of Biology and Medicine, Volume 41, pages 62-68, August 1968.
	AT	Schaffner, et al., "Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. II. Lysostaphin, in vivo Studies", Yale Journal of Biology and Medicine, Volume 39, pages, 230-244, February 1967.
	AU	Schaffner, et al., "Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. I. Lysostaphin in vitro Studies", Yale Journal of Biology and Medicine, Volume 39, pages 215-229, February 1967.
	AV	Kessler, et al., "Secreted LasA of <i>Pseudomonas aeruginosa</i> Is a Staphylolytic Protease", The Journal of Biological Chemistry, Volume 268, No. 10, pages 7503-7508 (1993).
	AW	Li, et al., "Purification, Staphylolytic Activity, and Cleavage Sites of α -Lytic Protease from <i>Achromobacter lyticus</i> ", The Journal of Biological Chemistry, Volume 122, No. 4, pages 772-778 (1997).
	AX	Oldham, et al., "Lysostaphin: Use of a Recombinant Bactericidal Enzyme as a Mastitis Therapeutic", J. Diary of Sci., 74:4175-4182 (1991).
	AY	Martin, et al., "The Selective Activity of Lysotaphin in vivo", The Journal of Laboratory and Clinical Medicine, Volume 70, No. 1, pages 1-8 (July 1967).
	AZ	Martin, et al., "The Reacquisition of Staphylococci by Treated Carriers: A Demonstration of Bacterial Interference", J. Lab. Clin. Med., Volume 71, No. 5, pages 791-797 (May 1968).
my	BA	Harrison et al., "Therapeutic Activity of Lysostaphin in Experimental Staphylococcal Infections", Canadian Journal of Microbiology, Volume 13, pages 93-97 (1967).

EXAMINER

DATE CONSIDERED

07/02

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 7732-020-27 DIV		SERIAL NO. 09/665,077	
				APPLICANT MICHAEL CLIMO, ET AL.			
				FILING DATE SEPTEMBER 19, 2000		GROUP ART UNIT 1631	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	BB						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES NO		
	BC						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
mm	BD	Schuhardt, et al., "Lysostaphin Therapy in Mice Infected with <i>Staphylococcus Aureus</i> ", J. Bacteriol., Volume 88, No. 1064, pages 815-816.					
f	BE	Harrison, et al., "Lysostaphin in Experimental Renal Infections", Journal of Bacteriology, pages 520-524, (February 1967).					
f	BF	Stark, et al., "Systemic Lysostaphin Man - Apparent Antimicrobial Activity in A Neutropenic Patient", The New England Journal of Medicine, pages 239-240 (August 1974).					
f	BG	Goldberg et al., "Studies in Experimental Staphylococcal Endocarditis in Dogs. VI. Treatment in Lysostaphin", Antimicrobial Agents and Chemotherapy, pages 45-53 (1967).					
mm	BH	Quickel, Jr. et al, "Efficacy and Safety of Topical Lysostaphin Treatment of Persistent Nasal Carriage of <i>Staphylococcus aureus</i> ", Applied Microbiology, pages 446-450 (September 1971).					
	BI						
	BJ						
	BK						
	BL						
	BM						
	BN						
	BO						
	BP						
	BQ						
	BR						
	BS						
	BT						
EXAMINER 					DATE CONSIDERED 07/02		
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							